First Quadrant L P CA boosted its holdings in shares of Allergan PLC. (NYSE:AGN) by 17.8% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,404 shares of the company’s stock after acquiring an additional 969 shares during the period. First Quadrant L P CA’s holdings in Allergan PLC. were worth $1,312,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AGN. Schroder Investment Management Group grew its holdings in Allergan PLC. by 133.3% during the 1st quarter. Schroder Investment Management Group now owns 417,948 shares of the company’s stock worth $100,225,000 after acquiring an additional 238,796 shares during the period. Dai Ichi Life Insurance Company Ltd grew its holdings in Allergan PLC. by 50.7% during the 1st quarter. Dai Ichi Life Insurance Company Ltd now owns 24,935 shares of the company’s stock worth $5,957,000 after acquiring an additional 8,394 shares during the period. Bank of Hawaii grew its holdings in Allergan PLC. by 55.8% during the 1st quarter. Bank of Hawaii now owns 10,343 shares of the company’s stock worth $2,471,000 after acquiring an additional 3,703 shares during the period. Leisure Capital Management acquired a new stake in Allergan PLC. during the 1st quarter worth $215,000. Finally, JNBA Financial Advisors grew its holdings in Allergan PLC. by 2.5% during the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock worth $116,000 after acquiring an additional 12 shares during the period. 82.02% of the stock is owned by hedge funds and other institutional investors.

AGN has been the subject of a number of analyst reports. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a report on Tuesday, July 11th. Piper Jaffray Companies reissued a “hold” rating and set a $231.00 price target on shares of Allergan PLC. in a research report on Friday, July 14th. Royal Bank Of Canada set a $284.00 price target on shares of Allergan PLC. and gave the stock a “buy” rating in a research report on Sunday, July 16th. Deutsche Bank AG reissued a “buy” rating and set a $273.00 price target (up from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Finally, Credit Suisse Group reissued an “outperform” rating and set a $286.00 price target (up from $274.00) on shares of Allergan PLC. in a research report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $246.73.

WARNING: “First Quadrant L P CA Has $1.31 Million Holdings in Allergan PLC. (AGN)” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/first-quadrant-l-p-ca-has-1-31-million-holdings-in-allergan-plc-agn/1677724.html.

Shares of Allergan PLC. (AGN) opened at $174.92 on Friday. The company has a market cap of $58.33 billion, a PE ratio of 11.37, a price-to-earnings-growth ratio of 0.93 and a beta of 1.13. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.10 and a current ratio of 2.13.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to analyst estimates of $4.04 billion. Allergan PLC. had a positive return on equity of 7.86% and a negative net margin of 47.27%. Allergan PLC.’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.32 EPS. equities research analysts expect that Allergan PLC. will post 16.28 EPS for the current year.

Allergan PLC. declared that its board has approved a share repurchase plan on Monday, September 25th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Friday, November 17th will be issued a $0.70 dividend. The ex-dividend date is Thursday, November 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.60%. Allergan PLC.’s payout ratio is currently -12.44%.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.